Outcomes in COVID-19 crizanlizumab studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -29% 2 463 Improvement, Studies, Patients Relative Risk Mortality -33% 1 421 RCTs -29% 2 463 Late -29% 2 463 Crizanlizumab for COVID-19 c19early.org November 2025 Favorscrizanlizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] 37/211 27/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk All studies -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk 1 crizanlizumab COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 serious outcomes c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) -35% 1.35 [0.89-2.06] no disch. 22 (n) 20 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Late treatment -35% 1.35 [0.89-2.06] 22 (n) 20 (n) 35% higher risk All studies -35% 1.35 [0.89-2.06] 22 (n) 20 (n) 35% higher risk 1 crizanlizumab COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] 37/211 27/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk All studies -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk 1 crizanlizumab COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CRITICAL Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control CRITICAL Leucker (DB RCT) 9% 0.91 [0.06-13.6] progression 1/22 1/20 CRITICAL Leucker (DB RCT) -35% 1.35 [0.89-2.06] no disch. 22 (n) 20 (n) ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 ACTIV-4a Solomon (RCT) -78% 1.78 [0.93-3.24] death 25/211 14/210 ACTIV-4a Solomon (RCT) -43% 1.43 [0.86-2.33] misc. 211 (n) 210 (n) Crizanlizumab COVID-19 outcomes c19early.org November 2025 Favors crizanlizumab Favors control